Trial Profile
An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2019
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 02 Apr 2019 Status changed from recruiting to completed.
- 28 Mar 2018 Status changed from not yet recruiting to recruiting.
- 14 Jun 2017 Planned primary completion date changed from 1 Nov 2019 to 15 Nov 2022.